becotatugvedotin plus gemcitabine

Preclinical

becotatugvedotin plus gemcitabine is one of 11 therapeutic programs targeting Pancreatic Ductal Adenocarcinoma (PDAC). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Preclinical

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Pancreatic Ductal Adenocarcinoma (PDAC)

#DrugCompanyPhaseTrials

Fotivda

Roche

Phase 2

1 2

Gemzar

Johnson & Johnson

Phase 2

1 3

Abraxane

Bristol-Myers Squibb

Phase 2

1 4

Erbitux

IImclone

Phase 2

1 5

Pumitamig

Bristol-Myers Squibb

Phase 2

1 6

Mfolfirinox

Incyte

Phase 2

1 7

Neoadjuvant Chemotherapy

JJapan Clinical Oncology Group

Phase 2

1 8

FAPI-74 PET/CT

SSOFIE

Phase 3

1 9

VS-7375

VVerastem, Inc.

Phase 2

1 10

BT5528

BBicycleTx Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalNot yet recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07685470

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

A Prospective, Single-arm, Ib/II Exploratory Study of Becotatugvedotin(MRG003) in Combination With Gemcitabine for Second-line Advanced Pancreatic Ductal Adenocarcinoma

Not yet recruiting·PPeking Union Medical College Hospital·Preclinical·NCT07685470·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for becotatugvedotin plus gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for becotatugvedotin plus gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: PPeking Union Medical College Hospital

becotatugvedotin plus gemcitabine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

References

Drug Info

Quick Facts

Related News